Harriet Margot Kluger MD

Professor of Medicine (Medical Oncology); Associate Director, Hematology/Oncology Fellowship Program; Assistant Cancer Center Director for Education and Training Yale School of Medicine

Join to View Full Profile

800 Howard AveYale Physicians Building 2ND floorNew Haven, CT 06519
Phone+1 203-688-4191
Fax+1 203-737-2617

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
Alameda Health System-Highland HospitalResidency, Internal Medicine, 1995 - 1996
University of New Mexico School of MedicineResidency, Internal Medicine, 1993 - 1995
Tel Aviv University SacklerClass of 1992

Certifications & Licensure

CA State Medical License 1995 - Present
CT State Medical License 2000 - 2026
FL State Medical License 2020 - 2022
NM State Medical License 1993 - 2000
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma Start of enrollment: 2006 Dec 01
Completed
Phase 2
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma Start of enrollment: 2011 Jun 01
Terminated
Phase 1, Phase 2
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. Start of enrollment: 2013 Jul 01
Terminated
Phase 1, Phase 2
Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases Start of enrollment: 2013 Apr 01
Completed
Phase 2
MK-3475 in Melanoma and NSCLC Patients With Brain Metastases Start of enrollment: 2014 Mar 01
Completed
Phase 2
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases Start of enrollment: 2015 Feb 01
Terminated
Phase 2
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2016 May 01
COMPLETED
PHASE2
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Start of enrollment: 2018 Jun 09
COMPLETED
PHASE1
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) Start of enrollment: 2020 Sep 14
ACTIVE_NOT_RECRUITING
PHASE1
Roles: Contact, Principal Investigator
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas Start of enrollment: 2018 Oct 24
Terminated
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Humoral determinants of checkpoint immunotherapy.
Yile Dai, Lilach Aizenbud, Kai Qin, Matthew Austin, Jillian R Jaycox
Nature. 2025-07-23
Lifileucel tumor-infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhib...
Harriet Kluger, Götz Ulrich Grigoleit, Sajeve Thomas, Evidio Domingo-Musibay, Jason A Chesney
Cancer Communications. 2025-07-22
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy.
Ryan J Sullivan, Anthony R Cillo, Robert L Ferris, Russell W Jenkins, Harriet M Kluger
Journal for Immunotherapy of Cancer. 2025-06-25

Journal Articles

Assessment of Age, Period, and Birth Cohort Effects and Trends in Merkel Cell Carcinoma Incidence in the United States
Harriet Kluger, MD, JAMA Dermatology
Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung Carcinoma
Beth A Hellerstedt, Nicholas J Vogelzang, Harriet M Kluger, Christopher A Yasenchak, Michael S Gordon, Primo Lara, Clinical Lung Cancer

Lectures

Updated Efficacy Studies of Anti-PD-1 Therapy and Associated Biomarkers
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
14th Therapeutic ERCP-EUS Workshop
Yale CME, New Haven, Connecticut - 3/23/2012
Yale Cancer Center Evening Oncology Series: Melanoma
Yale CME, New Haven, Connecticut - 3/15/2012

Authored Content

Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung CarcinomaOctober 2018

Press Mentions

New Insights into Why Immunotherapy Works for Some Patients with Cancer, Not OthersJuly 23rd, 2025
Lu and Aklilu Honored with 2025 Dostanic AwardJuly 14th, 2025
How Immune Checkpoint Inhibitors Can Induce DiabetesJuly 1st, 2025
Join now to see all

Grant Support

Immune Therapy for Brain MetastasisYALE UNIVERSITY2023–2028
Dual-isotope SPECT imaging and immunophenotyping of immune cells to determine response to immunotherapyYALE UNIVERSITY2023–2028
Dual-isotope SPECT imaging and immunophenotyping of immune cells to determine response to immunotherapyYALE UNIVERSITY2023–2028
YALE CANCER CENTER CALABRESI IMMUNO-ONCOLOGY TRAINING PROGRAMYALE UNIVERSITY2018–2028
Yale SPORE in Skin CancerYALE UNIVERSITY2006–2028
Models To Predict Prognosis And Benefit From Adjuvant Therapy In Renal Cell CarciNational Cancer Institute2011–2012
Predicting Melanoma Response To BAY 43-9006/ChemotherapyNational Cancer Institute2005–2008